One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis).
Hemorrhage
Lung neoplasms
Mortality
Risk
Thromboembolism
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
30
05
2022
revised:
20
07
2022
accepted:
27
07
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
epublish
Résumé
This subanalysis aimed to provide real-world data on venous thromboembolism (VTE) from patients with lung cancer in the Cancer-VTE Registry. The primary outcome was the number of baseline VTE events in patients with lung cancer. The 1-year cumulative incidences of symptomatic VTE; composite VTE (symptomatic and incidental VTE requiring treatment); bleeding; cerebral infarction, transient ischemic attack, and systemic embolic events; and all-cause death were calculated. Clinical trial registration: UMIN000024942. The study enrolled a total of 2377 patients with lung cancer; of these, 119 (5.0%) had VTE (six [0.3%], symptomatic, and 113 [4.8%], asymptomatic) and 14 (0.6%) had pulmonary embolism at baseline. During the follow-up period (mean, 337.7 d), the incidence was 0.6% for symptomatic VTE, 1.8% for composite VTE, 1.5% for bleeding events, 1.3% for cerebral infarction, transient ischemic attack, and systemic embolism, and 19.1% for all-cause death. Composite VTE frequency did not vary by anticancer drug type. Patients with (versus without) VTE at baseline had higher hazard ratios (HRs) for composite VTE (unadjusted HR: 5.29; Gray test Our findings emphasize the importance of VTE screening at cancer diagnosis.
Identifiants
pubmed: 36089919
doi: 10.1016/j.jtocrr.2022.100392
pii: S2666-3643(22)00116-3
pmc: PMC9460508
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100392Informations de copyright
© 2022 The Authors.
Références
JAMA. 2008 Nov 19;300(19):2277-85
pubmed: 19017914
Thromb Res. 2009;123 Suppl 4:S11-7
pubmed: 19303496
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Jun;39(6):454-8
pubmed: 27289575
Vasc Med. 2015 Apr;20(2):153-61
pubmed: 25832603
Arch Intern Med. 2006 Feb 27;166(4):458-64
pubmed: 16505267
J Natl Cancer Inst. 2012 Dec 5;104(23):1837-40
pubmed: 23093559
JAMA. 2005 Feb 9;293(6):715-22
pubmed: 15701913
Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):1291-1305
pubmed: 33567864
Respir Res. 2018 May 9;19(1):88
pubmed: 29743116
J Clin Oncol. 2012 Dec 10;30(35):4416-26
pubmed: 23150697
Br J Cancer. 2004 Jul 5;91(1):92-5
pubmed: 15226761
Br J Cancer. 2016 Jun 28;115(1):115-21
pubmed: 27253177
JACC CardioOncol. 2021 Apr 20;3(2):173-190
pubmed: 34396323
Jpn J Clin Oncol. 2020 Oct 22;50(11):1246-1253
pubmed: 32715307
Thromb Res. 2022 May;213:203-213
pubmed: 35282898
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
JAMA. 2019 Aug 27;322(8):764-774
pubmed: 31454018
BMC Cancer. 2020 May 24;20(1):461
pubmed: 32448219
Cancer Med. 2021 Feb;10(3):895-904
pubmed: 33421344
Br J Haematol. 2008 Oct;143(2):180-90
pubmed: 18783400
J Thorac Oncol. 2020 Sep;15(9):1497-1506
pubmed: 32437899
J Thromb Haemost. 2021 May;19(5):1250-1258
pubmed: 33605020
J Med Ultrason (2001). 2008 Mar;35(1):33-6
pubmed: 27278564
J Clin Oncol. 2009 Oct 10;27(29):4839-47
pubmed: 19720906
Cancer. 2007 Nov 15;110(10):2339-46
pubmed: 17918266
J Med Vasc. 2020 Nov;45(6S):6S8-6S16
pubmed: 33276943
BMJ Open. 2018 May 30;8(5):e018910
pubmed: 29848769
Eur Respir Rev. 2021 Jul 13;30(161):
pubmed: 34261744
Blood. 2021 Mar 25;137(12):1669-1678
pubmed: 33067632
Anesth Analg. 2017 Aug;125(2):403-412
pubmed: 28640782
Lancet. 2021 Jul 3;398(10294):64-77
pubmed: 33984268
J Cardiol. 2020 Jan;75(1):110-114
pubmed: 31416782
Int J Hematol. 2008 Apr;87(3):250-5
pubmed: 18283526
Cancer Manag Res. 2021 May 18;13:4031-4040
pubmed: 34040443